[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-cancers":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,69,99,121,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100612986","phase-1-clinical-trial-of-tqb2922-injection-subcutaneous-injection-in-patients-with-advanced-cancers-100612986",false,"NCT07260708","Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers","A Phase I Clinical Study to Evaluate The Safety and Pharmacokinetics of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers","Inclusion Criteria:\n\n* Subjects voluntarily joined this study, signed the informed consent form, and had good compliance；\n* 18-75 yeas old；\n* Eastern Cooperative Oncology Group Performance Status (ECOG) score: 0-1;\n* Expected survival of more than 12 weeks；\n* Histologically or cytologically diagnosed with advanced non-squamous non-small cell lung cancer\n* Subjects in the monotherapy introduction stage need to have received standard treatment or lack effective treatment.\n* There must be at least one measurable lesion within the radiotherapy area that can be clearly classified as progressive according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) criteria.\n* Major organs are functioning well；\n* Female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study.\n\nExclusion Criteria:\n\n* Current concomitant presence of other malignancies within 5 years prior to the first dose；\n* At the time of initiating the study of treatment, the adverse reactions caused by previous anti-tumor treatments failed to recover to a CTCAE 5.0 score of grade 1 or below.\n* Patients who had received major surgical treatment within 4 weeks prior to the first study, had obvious traumatic injuries, or were expected to undergo major surgery during the study treatment period, or had long-term unhealed wounds or fractures.\n* Hyperactive or venous thrombosis events occurred within 6 months before the first administration;\n* Major cardiovascular diseases;\n* Active hepatitis\n* Those with a history of psychotropic drug abuse who are unable to quit or have mental disorders.\n* There was an active infection (≥ Common Terminology Criteria for Adverse Events version 5.0 (CTCAE5.0) score of grade 2) within 2 weeks before the first administration;\n* Patients with renal failure requiring hemodialysis or peritoneal dialysis;\n* Patients who have a history of immune deficiency.\n* Patients who have epilepsy and need treatment;\n* Evidence of a previous history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any clinically active interstitial lung disease.\n* Those who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first treatment.\n* Pregnant or lactating women.\n* There is any serious or uncontrolled systemic disease.","ALL","18 Years","75 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.",[27],"Advanced Cancers","RECRUITING","2026-04-20",{"date":31,"type":32},"2026-04-21","ACTUAL",{"date":34,"type":32},"2025-12-16",{"date":36,"type":21},"2028-12",{"name":38,"class":39},"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","INDUSTRY",11,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100516225","phase-2-psilocybin-in-cancer-pain-study-100516225","NCT06001749","Psilocybin in Cancer Pain Study","Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer","Inclusion Criteria:\n\n* Participants must be 18 year old or older;\n* Participants must have advanced cancer, defined as a cancer that is unlikely to be cured or controlled with treatment;\n* Participants must have progressed on or be intolerant to approved therapies with a known clinical benefit (unless it is documented that they have refused such treatments);\n* Participants must evaluate their average pain on BPI Severity Scale ≥ 4\u002F10 over the past week;\n* Participants must receive chronic opioid pharmacotherapy for pain with an Oral Morphine Equivalent (OME) ≥ 200mg\u002Fday;\n* Participants must have been seen by a palliative care clinician either at DFCI, MGH or associated satellites in the last three months;\n* Participants must have an ECOG Performance Status ≤ 2\n* Participants must meet the following organ and marrow function on their last available bloodwork as defined below:\n\n  * Platelets ≥ 50,000\u002FmcL\n  * AST(SGOT)\u002FALT(SGPT) ≤ 5 × institutional ULN\n* Participants must be able to understand and willing to sign a written informed consent document\n* Participants must be able to swallow pills.\n* Participants must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.\n* Participants must agree to inform the investigators within 48 hours of any new medical conditions and procedures.\n* Participants must agree to the following lifestyle modifications (described in more detail in Section 3.4 Lifestyle Modifications):\n\n  * Comply with requirements for diet,\n  * Refrain from certain medications prior to Experimental Sessions,\n  * Be driven home after each Experimental Session,\n  * Commit to medication dosing, therapy, and study procedures.\n\nExclusion Criteria:\n\n* Participants who receive concurrent (less than four weeks or planned within 6 weeks) cytotoxic chemotherapy or radiation therapy that may impair general level of physical functioning or affect study outcomes;\n* Participants with a condition impairing oral intake or digestive absorption;\n* Participants who are not able to give adequate informed consent;\n* Participants who have a significant suicide risk as defined by suicidal ideation with intent and with or without a plan as endorsed on items 4 and\u002For 5 on the C-SSRS within the past 6 months or at V0\n* Participants who have a history of, or a current diagnostic of primary psychotic disorder, major depressive disorder with psychotic features, bipolar affective disorder type 1 or history of or current dissociative identity disorder; and participants who have an ongoing substance use disorder (defined as active in the past year). Participants with first-degree relatives with schizophrenia or bipolar disorder may be eligible depending on their age and personal and family psychiatric history. The decision will be made by the principal investigator and study psychiatrist based on risk assessment.\n* Participants for whom there is a potential for adverse drug-drug interactions. Concomitant medications with significant potential to interact with study medications will be exclusionary if they cannot be tapered. These include the following:\n\n  * Serotoninergic antidepressants\n  * Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)\n  * Tricyclic Antidepressants (TCAs)\n  * Efavirenz\n  * serotonin-acting dietary supplements (i.e. 5-hydroxy-tryptophan or St. John's wort)\n  * Centrally-acting serotonergic agents (e.g. MAO inhibitors)\n  * Antipsychotics (e.g. first and second generation)\n  * Mood stabilizers (e.g. lithium, valproic acid)\n  * Aldehyde dehydrogenase inhibitors (e.g. disulfiram)\n  * Significant inhibitors of UGT 1A0 or UGT 1A10 Any psychiatric medication will be tapered if possible in an appropriate fashion to avoid withdrawal effects. They will be discontinued long enough before the psilocybin Session to avoid the possibility of any drug-drug interaction (the interval will be at least five times the particular drug and active metabolites' half-life + one week for stabilization). See section 5.3 of the protocol for concomitant medications and tapering instructions.\n* Participants who have evidence or history of significant (controlled or uncontrolled) hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration (participants with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded).\n* Participants with brain tumors or brain metastases that haven't been successfully treated\n* Participants with lab abnormalities that may contribute to somnolence, confusion or delayed metabolism of psilocybin and\u002For with severe lab abnormalities (grade 3 or more per CTCAE scale).\n* Participants with a diagnosis of cirrhosis or liver failure\n* Participants who have uncontrolled hypertension using the standard criteria of the American Heart Association (values of 140\u002F90 milligrams of Mercury \\[mmHg\\] or higher assessed on three separate occasions)\n* Participants who have a heart rate \\> 100 bpm on three separate occasions\n* Participants who have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (PVCs) in the absence of ischemic heart disease.\n* Participants who have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation.\n* Participants who have a history of arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening. Participants with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia or any other arrhythmia associated with a bypass tract may be enrolled if they have been successfully treated.\n* Participants who have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)\n* Participants who have a history of myocardial infarction, coronary artery disease or heart failure\n* Participants who have a marked Baseline prolongation of QT\u002FQTc interval. For purposes of eligibility, this is defined as repeated demonstration of a QT interval corrected on the triplicate ECGs performed at screening, using Fridericia's formula \\[QTcF\\] \\> 450 milliseconds \\[ms\\] in males and \\> 460 ms in females.\n* For transgender or non binary participants, QTc interval will be evaluated based on sex assigned at birth, unless the participant has been on hormonal treatment for five or more years.\n* Women who are pregnant, nursing, or able to become pregnant and are not practicing an effective means of birth control. Acceptable methods of contraception are the following: intrauterine device, injected\u002F implanted\u002F intravaginal\u002F transdermal hormonal method, oral hormones plus a barrier contraception, abstinence, vasectomized sole partner, or double barrier contraception.\n* Participants who have hypersensitivity to any ingredient of the IMP (Investigational Medicinal Product).",{"count":49,"type":21},15,[51],"PHASE2","The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer.\n\nThe name of the study intervention used in this research study is:\n\nPsilocybin (a tryptamine derivative)",[54,55,56,57,27],"Opioid-Related Disorders","Pain Management","Pain Management and Care","Advanced Cancer",[54,55,56,57,27],"2025-12-15",{"date":34,"type":32},{"date":62,"type":32},"2024-09-23",{"date":64,"type":21},"2026-12-31",{"name":66,"class":67},"Yvan Beaussant, MD, MSci","OTHER",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":68},"100221093","personalized-oncogenomics-pog-program-of-british-columbia-100221093","NCT02155621","Personalized Oncogenomics (POG) Program of British Columbia","Personalized OncoGenomics (POG) Program of British Columbia: Connecting Cancer Genomics to Cancer Care","Inclusion criteria:\n\n1. Patients must agree to allow their archival specimens to be used and possibly completely depleted for these analyses.\n2. Willing and able to have a study-specific biopsy or resection of the tumour or metastatic site OR if there is adequate archival material available, either fresh frozen or FFPE (if specimen is thought to be adequate) that is taken after the most recent chemo or radiation. Ideally this sample should have been collected within 16 weeks of the date of consent. If archival tissue is not adequate and if a biopsy is not feasible or deemed medically safe by the investigators the patient would become ineligible.\n3. Patients must understand and agree to provide a blood test (or other sample of normal DNA) for germline genomic analysis.\n4. ECOG PS 0 or 1.\n5. Age \\>\u002F= 18 years.\n6. Estimated life expectancy \\>\u002F= 6 months and high likelihood of being clinically fit for a therapeutic clinical trial in 3-6 months.\n7. Measurable disease with RECIST v1.1 (or updated version).\n8. Adequate organ function.\n9. Patients must clearly understand that this data may be used to help guide treatment recommendations, including the avoidance of some therapeutic agents or the suggestion to use standard cytotoxic chemotherapy agents.\n10. Willingness to have their de-identified genomic and clinical data shared with national and international research collaborators and data sharing platforms (as detailed in the consent form).\n11. Willingness to be contacted for future studies based on the data that is generated by participation in POG; included in this is the anticipation that patient would be fit or a candidate for clinical trials.\n\nExclusion criteria:\n\n1. Unable or unwilling to consent to the above tissue and blood requirements.\n2. Significant medical condition that in the opinion of the treating or consenting oncologist and\u002For the POG central office review team renders the subject not suitable for participation. This includes the likelihood that a subject would be suitable for a clinical trial within 12 weeks after POG biopsy.\n3. Unwilling or unable to provide treatment and outcome follow up information to the BC Cancer or affiliated investigators.\n4. Unwilling to receive medically actionable findings (germline and\u002For somatic).","85 Years",{"count":78,"type":21},5000,[80],"NA","The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer \"drivers\" and corresponding drugs that may inhibit these pathways.",[83,27,84],"Metastatic Cancers","Cancers That Cannot be Treated With Curative Intent",[86,87,88,89],"cancer genomics","precision medicine","metastatic cancer","clinical decision-making","2025-09-17",{"date":92,"type":32},"2025-09-22",{"date":94,"type":4},"2014-07",{"date":96,"type":21},"2026-03",{"name":98,"class":67},"British Columbia Cancer Agency",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":68},"100566013","phase-1-a-multicenter-open-label-phase-i-clinical-trial-evaluating-the-safety-and-pharmacokinetics-of-tqb2252-injection-in-subjects-with-advanced-malignant-tumors-100566013","NCT06649656","A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors","Inclusion Criteria:\n\n* The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;\n* 18 years old ≤ 75 years old (calculated from the date of signing the informed consent form);\n* Electrocorticogram (ECOG) score ranges from 0 to 1 points;\n* Expected survival is greater than 12 weeks；\n* Confirmed to have at least one measurable lesion according to RECIST 1.1 (solid tumor) or Lugano 2014 (lymphoma) criteria；\n* Late stage malignant tumor subjects who have failed standard treatment or lack effective treatment；\n* Women of childbearing age should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study; Men should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study period.\n\nExclusion Criteria:\n\n* Has experienced or currently has other malignant tumors within the past 5 years prior to the first use of medication;\n* There are multiple factors that affect diseases related to intravenous injection and venous blood collection;\n* The adverse reactions of previous anti-tumor treatments have not recovered to a Common Terminology Criteria for Adverse Events (CTCAE) v5.0 score of ≤ 1;\n* Individuals who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication;\n* Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first administration;\n* An arterial\u002Fvenous thrombotic event occurred within 6 months prior to the first administration;\n* Active viral hepatitis with poor control;\n* Active syphilis infected individuals in need of treatment;\n* History of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or clinically symptomatic active pneumonia;\n* Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;\n* Diagnosed with immunodeficiency or undergoing systemic glucocorticoid therapy or any other form of immunosuppressive therapy due to a history of hepatic encephalopathy;\n* Previously experienced grade 3 or higher adverse reactions related to immunotherapy;\n* Suffering from significant cardiovascular disease;\n* Active or uncontrolled severe infections;\n* Patients with renal failure requiring hemodialysis or peritoneal dialysis;\n* History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases;\n* Individuals with epilepsy who require treatment;\n* Previously received treatment with similar anti-lag3 drugs.",true,{"count":107,"type":21},100,[24],"This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.",[27],"NOT_YET_RECRUITING","2024-10-17",{"date":114,"type":32},"2024-10-21",{"date":116,"type":21},"2024-11",{"date":118,"type":21},"2026-12",{"name":120,"class":39},"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":139,"locationsCount":68},"100547898","phase-1-a-clinical-study-of-tqb3107-tablets-in-patients-with-malignant-tumors-100547898","NCT06413953","A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors","A Phase I Clinical Study of Tolerability and Pharmacokinetics of TQB3107 Tablets in Patients With Malignant Tumors","Inclusion Criteria:\n\n* 18 years ≤ age≤ 75 years (calculated from the date of signing the informed consent); Score 0\\~1 point, estimated survival ≥ 3 months；\n* Malignant tumors with no standard treatment regimen or disease progression or intolerance after prior standard therapy；\n* The major organs are functioning well；\n* Negative serum pregnancy test within 7 days prior to the first dose and must be a non-lactating subject, female and male subjects of childbearing potential should agree to use contraception throughout the study and for 6 months after the study ends;\n* Subjects voluntarily participated in this study, signing the informed consent form and demonstrating good compliance.\n\nExclusion Criteria:\n\n* Hematologic malignancy has or is suspected to involve the central nervous system, or primary central nervous system lymphoma;\n* Received any anti-cancer therapy such as major surgery, chemotherapy and\u002For radiotherapy, immunotherapy, or targeted therapy within 4 weeks prior to the first dose;\n* Combined with severe or not well-controlled diseases, which the investigator judges to be at greater risk of entering this study；\n* Those with a history of drug addiction or substance abuse；\n* Based on the investigator's judgement, subjects with concomitant diseases that pose a significant risk to their safety or compromise the study's completion, or subjects deemed unsuitable for enrollment due to other reasons, will be excluded.",{"count":129,"type":21},140,[24],"TQB3107 is a protein inhibitor that induces apoptosis and inhibits the proliferation of various tumor cells. This clinical study aims to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).",[27],"2024-07-01",{"date":135,"type":32},"2024-07-03",{"date":137,"type":32},"2024-06-27",{"date":118,"type":21},{"name":140,"class":39},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":68},"100314627","phase-1-plasmodium-immunotherapy-for-advanced-cancers-100314627","NCT03375983","Plasmodium Immunotherapy for Advanced Cancers","Clinical Study of Plasmodium Immunotherapy for Advanced Cancers","Inclusion Criteria:\n\n* 18-70 years of age, male or female.\n* Patients with advanced cancer confirmed by histopathology and imaging; and imaging lesions of the tumor are clear and measurable, including but not limited to colon cancer, breast cancer, liver cancer, lung cancer, gastric cancer,sarcoma and other solid tumors (except for nasopharyngeal carcinoma, lymphatic cancer, cervical cancer and melanoma).\n* The time interval of the termination of chemotherapy (including interventional chemotherapy) or radiotherapy is at least 3 months for patients who had received chemotherapy (including interventional chemotherapy) or radiotherapy; at least 5 half-life for patients who had received targeted drug therapy (the half-life of targeted drug is according to the drug instructions);\n* All the patients who have not received surgery, radiotherapy, chemotherapy or targeted drug therapy and refuse to accept the above treatments must meet all the remaining requirements that listed in the inclusion criteria;\n* ECGO score of 0 or 1;\n* Expected survival ≥ 6 months;\n* PLT ≥100× 10\\^9\u002FL, NE ≥ 1.5 × 10\\^9\u002FL, and HGB ≥ 100 g\u002FL; no significant morphological abnormalities of red blood cells, or anemia (iron deficiency anemia, autoimmune hemolytic anemia, thalassemia, etc.);\n* The peripheral blood count of immune cells is close to normal or normal, the immune function test result is close to or at the level of normal population, and the function of heart, lung, liver and kidney are basically normal (the liver function classification of Child-push is A or B, Cr≤1.5×ULN);\n* Patient compliance meets the need for follow-up;\n* The subjects are able to understand and sign informed consent.\n\nExclusion Criteria:\n\n* Patients with severe hemoglobin disease or severe G6PD deficiency;\n* Patients with splenectomy or splenomegaly;\n* Patients with drug addiction or alcohol dependence;\n* With the following diseases or conditions: newly diagnosed with CNS metastasis ( excluding that the tumor lesions of the CNS has disappeared after treatment) and serious or uncontrolled systemic disease or any unstable systemic diseases (including but not limited to active infection, grade three hypertension, unstable angina, congestive heart failure, class III or IV heart disease, severe arrhythmia, liver and kidney dysfunction or metabolic disease), a clear history of neurological or psychiatric disorders, etc;\n* Accept any other anti-tumor treatment at the same time;\n* Patients with significantly lower immune function than those in the normal population;\n* Lung function is seriously damaged, the MNW \\\u003C39% or can't get out of bed, still feel short of breath when resting;\n* Rough cough, dyspnea, without normal diet or difficult to cooperate;\n* Poor body condition, the researchers assess that the patients can't tolerate the immune therapy;\n* Pregnant or lactating women;\n* Women of childbearing age with positive result for pregnancy tests;\n* Any condition that makes the subject ineligible to participate (in the opinion of the investigator).","70 Years",{"count":150,"type":21},20,[24,51],"The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.",[27],[155,156,157],"Advanced cancer","Plasmodium immunotherapy","Plasmodiun vivax","2024-02-17",{"date":160,"type":32},"2024-02-20",{"date":162,"type":32},"2017-11-23",{"date":164,"type":21},"2026-07-31",{"name":166,"class":39},"CAS Lamvac Biotech Co., Ltd."]